Related coverage linked through entity extraction aliases.
Apr 09, 2026
AbbVie updated its completed Phase 2 elezanumab study in acute traumatic cervical spinal cord injury. The placebo-controlled trial began in March 2020 and its latest public update was posted on February 9, 2026.
Mar 23, 2026
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
Feb 13, 2026
The European Commission has approved Gotenfia (golimumab), a biosimilar to Simponi developed by Bio-Thera and marketed by STADA, for chronic inflammatory autoimmune diseases across the EU and EEA.
